6/10sat.16:00～医局説明会を開催します☆

最近の投稿

• 6/10sat.16:00～医局説明会を開催します☆
• Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
• A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
• Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023 Feb 3:S0091-6749(23)00144-6.
• Dupilumab increases aspirin tolerance in NSAID exacerbated respiratory disease (N-ERD) Schneider S, et.al: Eur Respir J. 2022;in press